Investor Relations

Our mission is simple—help patients across the globe who suffer from pain and chronic conditions. We are doing this by harnessing the power of nVNS, innovation, and technology to develop a safe and clinically backed treatment. Bringing new treatments to market will help improve patients' treatment options and lives.

electroCore to Announce Fourth Quarter and Year Ended December 31, 2018 Financial Results on Wednesday, March 27

March 18, 2019 at 4:05 PM EDT
Conference Call to be Held at 4:30pm Eastern Time

BASKING RIDGE, N.J., March 18, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it will report fourth quarter and year ended December 31, 2018 financial results after the close of the market on Wednesday, March 27, 2019.  Management will host a conference call and webcast at 4:30pm Eastern Daylight Time to discuss the financial results and answer questions.

Wednesday, March 27th @ 4:30pm Eastern Daylight Time
Domestic: 877-407-4018
International: 201-689-8471
Conference ID: 13687710
Webcast: http://public.viavid.com/index.php?id=133315

About electroCore, Inc.

electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology and rheumatology. The company’s initial targets are the preventative treatment of cluster headache and acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

Investors:

Hans Vitzthum
LifeSci Advisors
617-535-7743
hans@lifesciadvisors.com

Media Contact:

Sara Zelkovic
LifeSci Public Relations
646-876-4933
sara@lifescipublicrelations.com

electroCore, Inc.